Reply by Authors

J Urol. 2020 Jan;203(1):127. doi: 10.1097/01.JU.0000604076.44320.a0. Epub 2019 Oct 14.

Shweta Dambal^{1

2}, Lauren E Howard³, Emma H Allott^{4

5}, William J Aronson^{6

7}, Christopher J Kane⁸, Christopher L Amling⁹, Matthew R Cooperberg¹⁰, Martha K Terris¹¹, Stephen J Freedland^{12

13}

¹ Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
² Eva Garland Consulting, Raleigh, North Carolina.
³ Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.
⁴ Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
⁵ Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
⁶ Urology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.
⁷ Department of Urology, UCLA School of Medicine, Los Angeles, California.
⁸ Urology Department, University of California-San Diego Health System, San Diego, California.
⁹ Department of Urology, Oregon Health Sciences University, Portland, Oregon.
¹⁰ Department of Urology, University of California-San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
¹¹ Sections of Urology, Veterans Affairs Medical Center Augusta and Medical College of Georgia, Augusta, Georgia.
¹² Division of Urology, Veterans Affairs Medical Center, Durham, North Carolina.
¹³ Cedars-Sinai Medical Center, Los Angeles, California.

No abstract available

Publication types